NCT06718387 Evaluation of the Impact of Participation in a Psycho-education Program for Victims of Sexual Violence
| NCT ID | NCT06718387 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Charles Perrens, Bordeaux |
| Condition | Ptsd |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-04-01 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-04-01 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Evaluation of the impact of a psycho-education program for victims of sexual violence, to determine the most efficient model to patients.
Eligibility Criteria
Inclusion Criteria: * At the suggestion of CRP therapists, * Patient treated at the CRP having been exposed to sexual violence Exclusion Criteria: \-
Contact & Investigator
Chantal BERGEY
PRINCIPAL INVESTIGATOR
Charles Perrens
Frequently Asked Questions
Who can join the NCT06718387 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Ptsd. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06718387 currently recruiting?
Yes, NCT06718387 is actively recruiting participants. Contact the research team at cbergey@ch-perrens.fr for enrollment information.
Where is the NCT06718387 trial being conducted?
This trial is being conducted at Bordeaux, France.
Who is sponsoring the NCT06718387 clinical trial?
NCT06718387 is sponsored by Centre Hospitalier Charles Perrens, Bordeaux. The principal investigator is Chantal BERGEY at Charles Perrens. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.